State of Alaska Department of Revenue raised its position in Allergan PLC. (NYSE:AGN) by 13.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,916 shares of the company’s stock after buying an additional 220 shares during the period. State of Alaska Department of Revenue’s holdings in Allergan PLC. were worth $465,000 as of its most recent filing with the SEC.
Several other hedge funds have also bought and sold shares of AGN. Veritas Asset Management LLP acquired a new stake in Allergan PLC. during the first quarter worth $761,339,000. Iridian Asset Management LLC CT increased its stake in Allergan PLC. by 141.3% in the first quarter. Iridian Asset Management LLC CT now owns 1,283,833 shares of the company’s stock worth $306,733,000 after buying an additional 751,848 shares during the period. Renaissance Technologies LLC acquired a new stake in Allergan PLC. during the first quarter worth $124,255,000. Blue Ridge Capital L.L.C. increased its stake in Allergan PLC. by 24.1% in the first quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock worth $456,313,000 after buying an additional 370,400 shares during the period. Finally, First Manhattan Co. increased its stake in Allergan PLC. by 193.3% in the first quarter. First Manhattan Co. now owns 497,793 shares of the company’s stock worth $114,646,000 after buying an additional 328,062 shares during the period. Hedge funds and other institutional investors own 83.63% of the company’s stock.
Shares of Allergan PLC. (NYSE AGN) traded down 0.011% during trading on Monday, reaching $223.965. 637,212 shares of the company’s stock were exchanged. The company has a 50 day moving average of $243.31 and a 200 day moving average of $238.68. The stock has a market cap of $74.87 billion, a P/E ratio of 6.824 and a beta of 1.16. Allergan PLC. has a 12-month low of $184.50 and a 12-month high of $256.80.
Allergan PLC. (NYSE:AGN) last announced its quarterly earnings data on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, beating analysts’ consensus estimates of $3.95 by $0.07. The firm had revenue of $4.01 billion during the quarter, compared to analysts’ expectations of $3.95 billion. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The business’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.35 earnings per share. Equities research analysts anticipate that Allergan PLC. will post $16.27 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be issued a $0.70 dividend. This represents a $2.80 dividend on an annualized basis and a dividend yield of 1.25%. The ex-dividend date of this dividend is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio (DPR) is currently 9.95%.
COPYRIGHT VIOLATION NOTICE: “State of Alaska Department of Revenue Raises Stake in Allergan PLC. (AGN)” was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this piece of content on another domain, it was stolen and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://sportsperspectives.com/2017/08/21/state-of-alaska-department-of-revenue-raises-stake-in-allergan-plc-agn.html.
AGN has been the topic of a number of research reports. Zacks Investment Research upgraded shares of Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 target price on the stock in a report on Tuesday, July 11th. Goldman Sachs Group, Inc. (The) downgraded shares of Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 target price on the stock. in a report on Wednesday, May 10th. Sanford C. Bernstein restated an “outperform” rating on shares of Allergan PLC. in a report on Thursday, May 25th. Royal Bank Of Canada boosted their target price on shares of Allergan PLC. from $279.00 to $284.00 and gave the stock an “outperform” rating in a report on Wednesday, May 10th. Finally, Deutsche Bank AG restated a “buy” rating and issued a $273.00 target price (up from $265.00) on shares of Allergan PLC. in a report on Monday, July 17th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and fifteen have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $275.49.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.